
Supplemental Online Content

Wang X, Wang S-S, Huang H, et al; South China Breast Cancer Group. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. *JAMA*. Published online December 10, 2021. doi:10.1001/jama.2020.23370

eFigure. Effect of Different Node Status on Outcomes **eTable.** Disease-Free Survival Events in 434 Patients With TNBC

This supplemental material has been provided by the authors to give readers additional information about their work.





Panel A: in the Subgroup of Patients with Node Negative Disease. Panel B: in the Subgroup of Patients with Node Positive Disease.

	Capecitabine group (n=221)	Observation group (n=213)
DFS event, n (%)	38 (17.2)	56 (26.3)
Locoregional invasive recurrence only	6 (2.7)	6 (2.8)
Distant recurrence only	26 (11.8)	34 (16.0)
Locoregional and distant recurrence	5 (2.3)	15 (7.0)
Death	1 (0.5)	1 (0.5)
Location of distant recurrence, n (%) *		
Bone	7 (3.2)	19 (8.9)
Lung	12 (5.4)	25 (11.7)
Liver	6 (2.7)	12 (5.6)
Brain	12 (5.4)	11 (5.2)
Other **	3 (1.4)	2 (0.9)

eTable. Disease-Free Survival Events in 434 Patients with TNBC

* The location of distant recurrence is not exclusive.

** Other sites included contralateral invasive breast cancer, the ovarian, pleura and peritoneum.